Abstract
Objective
The aim of this study was to develop and assess a radiomics model utilizing multiparametric magnetic resonance imaging (MRI) for the prediction of preoperative risk assessment in gastrointestinal stromal tumors (GISTs).Material and methods
An analysis was performed retrospectively on a group of 121 patients who received a histological diagnosis of GIST. They were then divided into two sets, with 85 in the training set and 36 in the validation set through random partitioning. Radiomics features from five MRI sequences, totaling 600 per patient, were extracted and subjected to feature selection utilizing a random forest algorithm. The discriminatory efficacy of the models was evaluated through receiver operating characteristic (ROC) and precision-recall (P-R) curve analyses. Model calibration was assessed via calibration curves. Subgroup analysis was performed on GISTs with a pathological maximum diameter equal to or less than 5 cm. Furtherly, Kaplan-Meier (K-M) curves and log-rank tests were used to compare the differences in survival status among different groups. Cox regression analysis was employed to identify independent prognostic factors and to construct a prognostic prediction model.Results
The clinical model (ModelC) displayed limited predictive efficacy in the context of GIST. Conversely, a radiomics model (ModelR) incorporating five parameters exhibited robust discriminative capabilities across both the training and validation sets, yielding area under the ROC curve (AUC) values of 0.893 (95% confidence interval [CI]: 0.807-0.949) and 0.855 (95% CI: 0.732-0.978), respectively. The F1max scores derived from the P‑R curves were 0.741 and 0.842 for the training and validation sets, respectively. Noteworthy was the exclusion of the two-dimensional tumor diameter and tumor location when constructing a hybrid model (ModelCR) that amalgamated radiomics and clinical features. ModelR demonstrated a substantially enhanced discriminative capacity in the training set compared with ModelC (p < 0.005). The net reclassification improvement (NRI) corroborated the superior performance of ModelR over ModelC, thereby enhancing diagnostic accuracy and clinical applicability. Patients in the high-risk group had significantly worse recurrence-free survival (RFS, p < 0.001) and overall survival (OS, p = 0.004), and the radiomics signature is an independent risk factor for RFS. The extended model incorporating the radiomics signature outperformed the baseline model in terms of risk assessment accuracy (p < 0.001).Conclusion
Our investigation underscores the value of integrating radiomics analysis in conjunction with machine learning algorithms for prognostic risk stratification in GIST, presenting promising implications for informing clinical decision-making processes as well as optimizing management strategies.References
Articles referenced by this article (30)
A Nomogram for Predicting Cancer-Specific Survival of Patients with Gastrointestinal Stromal Tumors.
Med Sci Monit, e922378 2020
MED: 32449506
Current clinical management of gastrointestinal stromal tumor.
World J Gastroenterol, (26):2806-2817 2018
MED: 30018476
Gastrointestinal stromal tumors: a comprehensive review.
J Gastrointest Oncol, (1):144-154 2019
MED: 30788170
Risk stratification of patients diagnosed with gastrointestinal stromal tumor.
Hum Pathol, (10):1411-1419 2008
MED: 18774375
Needle tract seeding after percutaneous biopsy of sarcoma: Risk/benefit considerations.
Cancer, (4):560-567 2016
MED: 27859013
Gastrointestinal stromal tumor. Correlation of computed tomography findings with tumor grade and mortality.
J Comput Assist Tomogr, (5):792-798 2003
MED: 14501372
Gastrointestinal stromal tumor: computed tomographic features.
J Med Assoc Thai, (9):1213-1219 2009
MED: 19772182
Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.
Clin Transl Imaging, (3):183-197 2017
MED: 29104864
Preliminary study of IVIM-DWI and DCE-MRI in early diagnosis of esophageal cancer.
Eur Rev Med Pharmacol Sci, (18):3345-3350 2015
MED: 26439027
Show 10 more references (10 of 30)